San Diego-centered Viking Therapeutics marked itself as a significant competitor in the weight loss drug market place in February following revealing promising data from the mid-stage demo of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection and in March the company un